| Cat. No. |
Product Name |
Information |
| PC-38236 |
MU-UNMC-1
Spike RBD-ACE2 inhibitor
|
MU-UNMC-1 is a potential small-molecule inhibitor of S-RBD and ACE-2 interaction, shows antiviral activity against SARS-CoV-2 with IC50 of 0.67 uM in human bronchial epithelial cells. |
| PC-38235 |
SB27012
Spike RBD-ACE2 inhibitor
|
SB27012 (SB 27012) is a small molecule PPI inhibitor of the Spike RBD-ACE2 interaction (IC50=7.7 uM in ELISA assays), binds ACE2 (Kd=210 nM) without affecting ACE2 enzymatic activity. |
| PC-38178 |
Ensitrelvir
3CLpro inhibitor
|
Ensitrelvir (S-217622, S217622) is the first oral, non-covalent, non-peptidic SARS-CoV-2 3C-like protease (3CLpro) inhibitor clinical candidate with biochemical IC50 of 13 nM, antiviral EC50 of 0.37 uM. |
| PC-35231 |
GC376
3CLpro inhibitor
|
GC376 (GC-376) is a broad-spectrum antiviral agent that inhibits 3C or 3C-like proteases (3Cpro or 3CLpro) of picornaviruses, noroviruses, and coronaviruses with IC50 of 0.96 (MD145), 0.82 (TGEV) and 0.2 uM (HRV) in FRET protease assays. |
| PC-28782 |
MAVDA-K-256 TFA
SARS-CoV-2 NSP14 inhibitor
|
MAVDA-K-256 TFA is a potent and selective inhibitor of SARS-CoV-2 mRNA cap guanine-N7 methyltransferase (MTase) NSP14 with IC50 of <0.15 nM, inhibits SARS-CoV-2 replication with IC50 of 24.6 nM in Huh-7.5 cells. |
| PC-28706 |
CKP-25
Spike RBD/ACE2 inhibitor
|
CKP-25 is a small molecule severe-acute-respiratory syndrome coronavirus 2 (SARS-CoV-2) inhibitor, suppresses the Spike RBD/ACE2 (19-615) interaction, reduces the cytopathic effect of SARS-CoV-2 in Vero E6 cells with IC50 of 3.5 uM, reduces the viral load in cell culture supernatants. |
| PC-28371 |
1’-cyanocytidine
SARS-CoV-2 RdRp inhibitor
|
1'-cyanocytidine (CNC) is a nontoxic, next-generation nucleoside analog that displays submicromolar inhibition of SARS-CoV-2 replication with EC50 of 0.6-2.1 uM, targeting the viral RNA-dependent RNA polymerase (RdRp). |
| PC-28225 |
SM142
Mpro/CatL inhibitor
|
SM142 is a potent, selective peptidomimetic dual inhibitor of SARS-CoV-2 main protease (MPro) and host cathepsin L (CatL) with IC50 of 1.8 uM and 0.145 uM respectively. |
| PC-28224 |
SM141
Mpro/CatL inhibitor
|
SM141 is a potent, selective peptidomimetic dual inhibitor of SARS-CoV-2 main protease (MPro) and host cathepsin L (CatL) with IC50 of 0.9 uM and 0.06 uM respectively. |
| PC-27892 |
mCMX110
SARS-CoV-2 Mpro inhibitor
|
mCMX110 is a potent, selective, orally bioavailable SARS-CoV-2 main protease (Mpro) inhibitor with IC50 of 35 nM. |
| PC-26986 |
ACE2 inhibitor MB-32
ACE2 inhibitor
|
MB‑32 is a specific, allosteric inhibitor of angiotensin‑converting enzyme 2 (ACE2) with KD of 7.078 and 3.997 uM in SPR and BLI assays, selectively disrupts binding of SARS‑CoV‑2 spike receptor‑binding domain to ACE2, MB-32 is a potent and specific broad-spectrum entry inhibitor of pan-sarbecoviruses. |
| PC-26746 |
CG-0988
SARS-CoV-2 3CLpro inhibitor
|
CG-0988 is a potent, covalent SARS-CoV-2 3C-like protease (3CLpro) inhibitor with IC50 of 8.5 nM, demonstrates excellent antiviral activity with EC50 of 4.0 nM against Omicron EG.5.1. |
